| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jordi Bruix | Q37393143 |
| María Reig | Q54267038 | ||
| P2093 | author name string | Alejandro Forner | |
| Marco Sanduzzi-Zamparelli | |||
| Álvaro Díaz-González | |||
| Leonardo G Da Fonseca | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma | Q24540058 | ||
| Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA | Q24672943 | ||
| Diagnosis of Pathologically Early HCC with EOB-MRI: Experiences and Current Consensus | Q27027855 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma | Q28314897 | ||
| Institutional Decision to Adopt Y90 as Primary Treatment for HCC Informed by a 1,000-patient 15-year Experience. | Q47384456 | ||
| Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations | Q47650366 | ||
| Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. | Q47788877 | ||
| The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial | Q48238287 | ||
| Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study | Q50016823 | ||
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 | ||
| SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 | ||
| Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. | Q50474760 | ||
| Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. | Q50535030 | ||
| Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. | Q51472261 | ||
| Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver | Q29616866 | ||
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis | Q29619508 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography | Q31118557 | ||
| Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. | Q33375908 | ||
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 | ||
| Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 | ||
| Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation | Q34505935 | ||
| Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis | Q34585175 | ||
| Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. | Q34585928 | ||
| Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma | Q34593071 | ||
| The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis | Q34614340 | ||
| Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis | Q34616975 | ||
| Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. | Q34635723 | ||
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 | ||
| GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis | Q34693220 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis | Q35537922 | ||
| Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis | Q35858656 | ||
| Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis | Q35900872 | ||
| Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta-analysis | Q36051492 | ||
| A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma | Q36747407 | ||
| PD-1 and PD-1 ligands: from discovery to clinical application | Q36868261 | ||
| Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone | Q37138263 | ||
| Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma | Q37179530 | ||
| Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis | Q37341959 | ||
| Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. | Q37932735 | ||
| Primovist, Eovist: what to expect? | Q38002724 | ||
| Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker | Q38080832 | ||
| Treatment of intermediate-stage hepatocellular carcinoma | Q38236876 | ||
| SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. | Q52677129 | ||
| Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma. | Q53052270 | ||
| Is portal hypertension a contraindication to hepatic resection? | Q53061460 | ||
| Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. | Q53160804 | ||
| Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. | Q53192468 | ||
| Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. | Q53508322 | ||
| Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. | Q53841771 | ||
| Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features. | Q54418028 | ||
| Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. | Q54526554 | ||
| AASLD guidelines for the treatment of hepatocellular carcinoma | Q56172239 | ||
| Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial | Q56355520 | ||
| Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | Q56373211 | ||
| Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry | Q56378319 | ||
| Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study | Q56384328 | ||
| Immunotherapy of hepatocellular carcinoma | Q56896669 | ||
| Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study | Q56979113 | ||
| Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis | Q56985572 | ||
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57051799 | ||
| Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients | Q57150838 | ||
| Introduction to the Liver Imaging Reporting and Data System (LI-RADS) for hepatocellular carcinoma | Q57468271 | ||
| Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial | Q57762740 | ||
| Liver Toxicity with Cancer Checkpoint Inhibitor Therapy | Q57784047 | ||
| Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial | Q58020775 | ||
| Hepatocellular carcinoma | Q58020832 | ||
| Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound | Q58021493 | ||
| Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial | Q58236593 | ||
| Liver transplantation in patients with hepatocellular carcinoma across Milan criteria | Q58283868 | ||
| Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success | Q58554090 | ||
| Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial | Q58776805 | ||
| Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy | Q58811082 | ||
| Optimization of imaging diagnosis of 1–2cm hepatocellular carcinoma: An analysis of diagnostic performance and resource utilization | Q61736906 | ||
| Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria | Q63190284 | ||
| Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats | Q80678101 | ||
| Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? | Q86935141 | ||
| Laparoscopic versus open liver resection for hepatocellular carcinoma: Case-matched study with propensity score matching | Q87112238 | ||
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Q89012806 | ||
| Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma | Q91057809 | ||
| Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q91147767 | ||
| Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy | Q91332386 | ||
| Diagnosis of Hepatic Nodules in Patients at Risk for Hepatocellular Carcinoma: LI-RADS Probability Versus Certainty | Q91677922 | ||
| Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review | Q93174239 | ||
| Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence | Q93188937 | ||
| Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. | Q38248394 | ||
| Recent advances in the prevention of hepatocellular carcinoma recurrence | Q38264957 | ||
| Transarterial chemoembolization and radioembolization. | Q38264958 | ||
| Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial | Q38391922 | ||
| Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center | Q38500293 | ||
| Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation | Q38607787 | ||
| Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study | Q38683491 | ||
| Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. | Q38711169 | ||
| Diagnostic Performance of Gadoxetic Acid-enhanced Liver MR Imaging versus Multidetector CT in the Detection of Dysplastic Nodules and Early Hepatocellular Carcinoma | Q38727935 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| Predictive biomarkers for checkpoint inhibitor-based immunotherapy | Q38786289 | ||
| Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis | Q38869595 | ||
| The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib. | Q38944418 | ||
| In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 | ||
| Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. | Q38993647 | ||
| Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients | Q39594987 | ||
| The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study | Q39766876 | ||
| Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma | Q39876709 | ||
| Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma | Q39926325 | ||
| Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. | Q40068184 | ||
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 | ||
| Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial | Q40548309 | ||
| CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial | Q41155310 | ||
| Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation | Q41208111 | ||
| Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. | Q41489415 | ||
| Metroticket 2.0 Model for Analysis of Competing Risks of Death Following Liver Transplantation for Hepatocellular Carcinoma. | Q41921865 | ||
| Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation | Q42612881 | ||
| Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity | Q42775676 | ||
| A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. | Q42989841 | ||
| Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. | Q43647764 | ||
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 | ||
| The role of hepatic resection in the treatment of hepatocellular cancer | Q43752461 | ||
| Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging | Q43883499 | ||
| Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design | Q43950860 | ||
| Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. | Q44401177 | ||
| Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma | Q45001797 | ||
| Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. | Q45161424 | ||
| Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2 cm in a hepatitis B virus-endemic area. | Q45365065 | ||
| Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. | Q45809695 | ||
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 | ||
| Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats | Q46167132 | ||
| Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI. | Q47326179 | ||
| Characteristics of Hypovascular versus Hypervascular Well-Differentiated Hepatocellular Carcinoma Smaller Than 2 cm - Focus on Tumor Size, Markers and Imaging Detectability | Q47352649 | ||
| Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial | Q47376936 | ||
| P433 | issue | 1 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 17-29 | |
| P577 | publication date | 2019-03-18 | |
| P1476 | title | Controversies in the management of hepatocellular carcinoma | |
| P478 | volume | 1 |
Search more.